XML 178 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SHARE OPTION PLANS AND ESPP (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement, Recognized Amount [Abstract]  
Schedule of stock option plans
A summary of the status of the Company’s option plans as of March 31, 2024 and changes during the period then ended is presented below:
Three months ended March 31, 2024
Unaudited
Number
of options		Weighted
average
exercise
price
Outstanding at beginning of year8,539,507 $40.07 
Granted3,456,485 15.35 
Exercised(26,547)8.70 
Forfeited and canceled(180,377)58.72 
Outstanding as of March 31, 202411,789,068 $32.61 
Exercisable options6,990,097 $34.67 
Schedule of RSUs and PSUs
A summary of the status of the Company’s RSUs and PSUs as of March 31, 2024 and changes during the period then ended is presented below.
Three months ended March 31, 2024
Unaudited
Number
of RSU/PSUs		Weighted
average
grant date fair value
Unvested at beginning of year5,813,066 $60.52 
Granted8,930,183 15.17 
Vested(501,473)90.19 
Forfeited and cancelled(337,925)74.50 
Unvested as of March 31, 2024 (1)13,903,851 29.98 

(1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones that are not probable as of March 31, 2024, in accordance with ASC 718 "Compensation — Stock Compensation" as follows:
 March 31, 2024
Number of
PSUs		Fair value at grant date per PSUTotal fair value at grant date
588,952 $16.30 $9,600 
2,703,852 $48.16 $130,218 
220,533 76.97 16,974 
249,402 80.59 20,099 
15,210 87.66 1,333 
3,777,949 $178,226 
Schedule of fair value assumptions used for All equity based awards estimated using black-scholes option pricing model
The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. The Company assessed fair value using the following underlying assumptions: 
Three months ended March 31,Year ended December 31,
2023
20242023
UnauditedAudited
Stock Option Plans
Expected term (years)
5.73-5.73
5.75-6.00
5.50-6.00
Expected volatility
71%-72%
63%-64%
63%-70%
Risk-free interest rate
3.88%-4.28%
4.08%-4.10%
3.48%-4.79%
Dividend yield0.00 %0.00 %0.00 %
ESPP
Expected term (years)0.500.500.50
Expected volatility90 %56 %
56%-122%
Risk-free interest rate5.13 %4.76 %
4.76%-5.38%
Dividend yield0.00 %0.00 %0.00 %
Schedule of non-cash share-based compensation expense related to company's equity-based awards
The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three months ended March 31, 2024 and 2023, and the year ended December 31, 2023 was:
Three months ended March 31,Year ended December 31,
2023
20242023
UnauditedAudited
Cost of revenues$1,747 $2,006 $6,587 
Research, development and clinical studies8,610 11,779 31,827 
Sales and marketing11,048 11,644 35,968 
General and administrative12,679 13,655 41,226 
Total share-based compensation expense$34,084 $39,084 $115,608